Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.

Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.

Item

http://www.wikidata.org/entity/Q44803518

Q44803518

about

HMG CoA reductase inhibitors (statins) for kidney transplant recipients HMG CoA reductase inhibitors (statins) for kidney transplant recipients Fish oil for kidney transplant recipients Fish oil for kidney transplant recipients Dyslipidemia and its therapeutic challenges in renal transplantation Transplant data: sources, collection and research considerations, 2004.mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.Relationships between serum lipid, lipoprotein, triglyceride-rich lipoprotein, and high-density lipoprotein particle concentrations in post-renal transplant patients.Primary care of the renal transplant patient.Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232].How can we manage hyperlipidemia and avoid rhabdomyolysis in transplant patients?Dyslipidemia in chronic kidney disease: managing a high-risk combination.The transplant patient and transplant medicine in family practice Characterization of clinical and genetic risk factors associated with dyslipidemia after kidney transplantation Reliable individualized monitoring improves cholesterol control in kidney transplant recipients.Reverse epidemiology: a spurious hypothesis or a hardcore reality?Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.Implementation of guidelines for metabolic syndrome control in kidney transplant recipients: results at a single center.Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.Kidney disease after heart and lung transplantation.Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes The quality of cardiovascular disease care for adolescents with kidney disease: a Midwest Pediatric Nephrology Consortium study.Corticosteroid withdrawal in kidney transplantation: the present status.Statin use is associated with prolonged survival of renal transplant recipients.Management of dyslipidemia in patients after solid organ transplantation.Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients.Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management.Dyslipidemia after kidney transplantation and correlation with cyclosporine level.The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients.Dyslipidemia can be controlled in diabetic as well as nondiabetic recipients after kidney transplant.Dyslipidemia after kidney transplantation and correlation with cyclosporine level: a glimpse into the future.Diet-induced increase in plasma oxidized LDL promotes early fibrosis in a renal porcine auto-transplantation model.Long-term management of the kidney transplant recipient.Renal complications following lung and heart-lung transplantation.Diabetes and kidney transplantation: past, present, and future.Examining the safety of PPAR agonists - current trends and future prospects.Comprehensive Care of the Lung Transplant Patient.Effect of a Short-Course Treatment with Synbiotics on Plasma p-Cresol Concentration in Kidney Transplant Recipients.Dietary intake as a link between obesity, systemic inflammation, and the assumption of multiple cardiovascular and antidiabetic drugs in renal transplant recipients.Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients.

P2860

Q24200984-947A0D32-FC8F-411D-8DC9-4EBAD7097432 Q24241098-FB01CCAD-F162-44BE-8D9E-664B757D6C1D Q24245378-0CF5DCD3-AE2B-4631-AE81-565498C40910 Q26470403-F420086A-1350-4766-B28E-7A4DD954CCB2 Q26851294-8CACF327-A71E-4A10-A60D-DAADEFBE8F17 Q30984607-6583A3B0-8125-4D52-9EF1-23097B046C62 Q33424013-23A5FB91-86D3-49FC-85AF-ED1E4A88F2AB Q33781024-3D201F08-8392-4D6D-A2C1-E61B1B2DA598 Q33898744-6103EE73-39BA-4D9B-8DF9-CC6093FA5FE0 Q34599557-42F88037-497D-46F1-92F6-82B412A5206B Q34808267-60A2A0B3-E972-4352-984B-D8F58A3919D9 Q35014627-A0AC8319-23A6-4951-AAE8-887D92A867FF Q35029807-30A8BFC1-9EF1-47C1-9D2F-C202FC5220F4 Q35476894-8E217A7B-726E-4A3B-B918-274FA9DB79E1 Q35948762-B58E76C1-C05D-4BB4-8332-A091E6A8C39F Q35997678-CFC2D9A9-19A4-4825-8A7B-4A96D410B2D5 Q36163801-0138DC75-07B5-457E-9922-5CB8DF3F982E Q36172191-7E48523F-43B4-4E24-8D28-D40BEE368EF9 Q36349758-3FA35922-732A-4BC7-B70B-595A63BAA7E9 Q36422125-D06BBCDE-D3D9-4A7C-AC76-E26E7609C54A Q36541052-E30BC535-1E32-451E-8BEC-48C0917FFFF6 Q36799725-905DA997-EA63-4341-9182-730D6E74F793 Q36909355-4FCDEE6C-BF88-403E-B44B-45ECB97B71C0 Q36949237-D8E35121-C2FE-4A39-A01D-FAAE6C10C36D Q37158327-1407E754-F86A-44AA-8E02-D0B233DC9B55 Q37176562-3CBE1671-DAE7-4413-9C99-54C27FC98320 Q37271270-6ED4274A-D7D8-4830-BDF4-C60C9BC997B7 Q37316487-0A6CC2F4-FC3D-4C6B-9DB5-7B3D1E7EBFDB Q37320962-74077D19-3FF1-4EC9-9357-FC66B3731A26 Q37389078-C962F045-C99F-46CF-96EB-27F23E5A254A Q37639119-53F34B5C-159F-45B1-93E6-B6BC3B2DEFD1 Q37714689-8FB8BDE6-431A-4919-92C1-D121F7354AEE Q37978101-5BB3660E-6F80-4069-B6BE-555314B027D1 Q38021674-0E5B9DDD-C274-4CCE-9803-2334C3CB474C Q38032801-293CC14E-A430-4565-BA26-816AF4BE1E31 Q38058381-090A58B0-FC57-422D-9C4E-3AC05212F018 Q38978203-1E2DE660-DD2A-471F-98FB-4EB14A37A316 Q40051571-7D1698FD-788D-4B09-B1A6-26B1CCEBCEF4 Q42208011-A8A792CA-3AEC-4B5A-A256-47AD23D43437 Q42837781-70F6ED83-85B3-4073-AEA2-DB5C43DEFF64

P2860

Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.

Item

http://www.wikidata.org/entity/Q44803518

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Clinical practice guidelines f ...... e Outcomes Quality Initiative.

@en

Clinical practice guidelines f ...... e Outcomes Quality Initiative.

@nl

type

Item

label

Clinical practice guidelines f ...... e Outcomes Quality Initiative.

@en

Clinical practice guidelines f ...... e Outcomes Quality Initiative.

@nl

prefLabel

Clinical practice guidelines f ...... e Outcomes Quality Initiative.

@en

Clinical practice guidelines f ...... e Outcomes Quality Initiative.

@nl

P1476

Clinical practice guidelines f ...... e Outcomes Quality Initiative.

@en

P2093

A Levin

http://www.w3.org/2001/XMLSchema#string

B Kasiske

http://www.w3.org/2001/XMLSchema#string

B M Chavers

http://www.w3.org/2001/XMLSchema#string

B Masri

http://www.w3.org/2001/XMLSchema#string

C Wanner

http://www.w3.org/2001/XMLSchema#string

D C Wheeler

http://www.w3.org/2001/XMLSchema#string

F G Cosio

http://www.w3.org/2001/XMLSchema#string

J Beto

http://www.w3.org/2001/XMLSchema#string

K Bolton

http://www.w3.org/2001/XMLSchema#string

National Kidney Foundation

http://www.w3.org/2001/XMLSchema#string

P2860

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

Aspirin for the primary prevention of cardiovascular events: recommendation and rationale

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

The interaction of diltiazem with simvastatin

Reduction of Serum Cholesterol with Sitostanol-Ester Margarine in a Mildly Hypercholesterolemic Population

Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

Progression of diabetic nephropathy.

Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients.

P304

13-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1600-6135.2004.0355.X

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

4 Suppl 7

http://www.w3.org/2001/XMLSchema#string

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8673270

http://www.w3.org/2001/XMLSchema#string

P698

15027968

http://www.w3.org/2001/XMLSchema#string

P921

patient

dyslipidemias

Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.

about

P2860

P2860

Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P5875

P698

P921